nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—liver cancer—colon cancer	0.384	1	CtDrD
Sorafenib—BRAF—colon cancer	0.186	0.844	CbGaD
Sorafenib—RALBP1—Vincristine—colon cancer	0.0712	0.31	CbGbCtD
Sorafenib—ABCB1—colon cancer	0.0344	0.156	CbGaD
Sorafenib—UGT1A9—Irinotecan—colon cancer	0.0172	0.0749	CbGbCtD
Sorafenib—UGT1A1—Irinotecan—colon cancer	0.014	0.0612	CbGbCtD
Sorafenib—ABCC4—Fluorouracil—colon cancer	0.0138	0.0601	CbGbCtD
Sorafenib—ABCC2—Irinotecan—colon cancer	0.00854	0.0373	CbGbCtD
Sorafenib—ABCG2—Irinotecan—colon cancer	0.00772	0.0337	CbGbCtD
Sorafenib—ABCC4—Methotrexate—colon cancer	0.0076	0.0331	CbGbCtD
Sorafenib—ABCC2—Vincristine—colon cancer	0.00746	0.0326	CbGbCtD
Sorafenib—ABCG2—Fluorouracil—colon cancer	0.00741	0.0323	CbGbCtD
Sorafenib—ABCG2—Vincristine—colon cancer	0.00675	0.0294	CbGbCtD
Sorafenib—CYP3A7—Irinotecan—colon cancer	0.0057	0.0249	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Irinotecan—colon cancer	0.0057	0.0249	CbGbCtD
Sorafenib—CYP2B6—Irinotecan—colon cancer	0.00543	0.0237	CbGbCtD
Sorafenib—CYP3A7—Vincristine—colon cancer	0.00498	0.0217	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Vincristine—colon cancer	0.00498	0.0217	CbGbCtD
Sorafenib—CYP2C9—Capecitabine—colon cancer	0.00464	0.0203	CbGbCtD
Sorafenib—ABCC2—Methotrexate—colon cancer	0.00452	0.0197	CbGbCtD
Sorafenib—CYP3A5—Irinotecan—colon cancer	0.00428	0.0187	CbGbCtD
Sorafenib—ABCG2—Methotrexate—colon cancer	0.00409	0.0178	CbGbCtD
Sorafenib—CYP2C8—Fluorouracil—colon cancer	0.00395	0.0172	CbGbCtD
Sorafenib—CYP3A5—Vincristine—colon cancer	0.00374	0.0163	CbGbCtD
Sorafenib—CYP1A2—Fluorouracil—colon cancer	0.00306	0.0133	CbGbCtD
Sorafenib—ABCB1—Irinotecan—colon cancer	0.00278	0.0121	CbGbCtD
Sorafenib—CYP2C9—Fluorouracil—colon cancer	0.00275	0.012	CbGbCtD
Sorafenib—ABCB1—Vincristine—colon cancer	0.00243	0.0106	CbGbCtD
Sorafenib—KIT—myenteric nerve plexus—colon cancer	0.00175	0.0386	CbGeAlD
Sorafenib—CYP3A4—Irinotecan—colon cancer	0.00167	0.00728	CbGbCtD
Sorafenib—Regorafenib—BRAF—colon cancer	0.00153	0.751	CrCbGaD
Sorafenib—ABCB1—Methotrexate—colon cancer	0.00147	0.00643	CbGbCtD
Sorafenib—CYP3A4—Vincristine—colon cancer	0.00146	0.00636	CbGbCtD
Sorafenib—FLT1—umbilical vein—colon cancer	0.00109	0.0241	CbGeAlD
Sorafenib—RAF1—Topotecan—Irinotecan—colon cancer	0.000954	0.569	CbGdCrCtD
Sorafenib—KDR—umbilical vein—colon cancer	0.000926	0.0204	CbGeAlD
Sorafenib—ABCC2—bile—colon cancer	0.000915	0.0201	CbGeAlD
Sorafenib—TIE1—endothelium—colon cancer	0.000808	0.0178	CbGeAlD
Sorafenib—TIE1—blood vessel—colon cancer	0.000745	0.0164	CbGeAlD
Sorafenib—CDK7—Topotecan—Irinotecan—colon cancer	0.000723	0.431	CbGdCrCtD
Sorafenib—FLT4—endothelium—colon cancer	0.000667	0.0147	CbGeAlD
Sorafenib—FLT4—blood vessel—colon cancer	0.000616	0.0136	CbGeAlD
Sorafenib—FLT1—endothelium—colon cancer	0.000519	0.0114	CbGeAlD
Sorafenib—FLT1—blood vessel—colon cancer	0.000479	0.0105	CbGeAlD
Sorafenib—KDR—endothelium—colon cancer	0.000439	0.00966	CbGeAlD
Sorafenib—CDK7—renal system—colon cancer	0.000425	0.00937	CbGeAlD
Sorafenib—PDGFRA—gall bladder—colon cancer	0.000422	0.00929	CbGeAlD
Sorafenib—KDR—blood vessel—colon cancer	0.000405	0.00891	CbGeAlD
Sorafenib—KIT—endothelium—colon cancer	0.000389	0.00856	CbGeAlD
Sorafenib—FLT4—embryo—colon cancer	0.000367	0.00809	CbGeAlD
Sorafenib—TIE1—epithelium—colon cancer	0.000363	0.00798	CbGeAlD
Sorafenib—HIPK3—renal system—colon cancer	0.00036	0.00792	CbGeAlD
Sorafenib—KIT—blood vessel—colon cancer	0.000359	0.0079	CbGeAlD
Sorafenib—CDK7—lymphoid tissue—colon cancer	0.000353	0.00778	CbGeAlD
Sorafenib—PDGFRB—blood vessel—colon cancer	0.00035	0.00771	CbGeAlD
Sorafenib—TIE1—smooth muscle tissue—colon cancer	0.000349	0.00769	CbGeAlD
Sorafenib—KIT—gall bladder—colon cancer	0.000337	0.00743	CbGeAlD
Sorafenib—PDGFRB—gall bladder—colon cancer	0.00033	0.00726	CbGeAlD
Sorafenib—RET—embryo—colon cancer	0.000324	0.00714	CbGeAlD
Sorafenib—TAOK2—vagina—colon cancer	0.000306	0.00673	CbGeAlD
Sorafenib—ZAK—lymphoid tissue—colon cancer	0.000305	0.00672	CbGeAlD
Sorafenib—ZAK—digestive system—colon cancer	0.000302	0.00664	CbGeAlD
Sorafenib—FLT4—epithelium—colon cancer	0.0003	0.0066	CbGeAlD
Sorafenib—HIPK3—digestive system—colon cancer	0.000295	0.0065	CbGeAlD
Sorafenib—FLT1—embryo—colon cancer	0.000285	0.00629	CbGeAlD
Sorafenib—RAF1—embryo—colon cancer	0.000284	0.00625	CbGeAlD
Sorafenib—Regorafenib—ABCB1—colon cancer	0.000283	0.139	CrCbGaD
Sorafenib—UGT1A9—renal system—colon cancer	0.000282	0.00621	CbGeAlD
Sorafenib—HIPK3—bone marrow—colon cancer	0.000272	0.00599	CbGeAlD
Sorafenib—MKNK2—epithelium—colon cancer	0.000271	0.00597	CbGeAlD
Sorafenib—MAP3K7—smooth muscle tissue—colon cancer	0.00027	0.00594	CbGeAlD
Sorafenib—PDGFRA—embryo—colon cancer	0.000268	0.00589	CbGeAlD
Sorafenib—ZAK—vagina—colon cancer	0.000266	0.00587	CbGeAlD
Sorafenib—RET—epithelium—colon cancer	0.000265	0.00583	CbGeAlD
Sorafenib—MKNK2—smooth muscle tissue—colon cancer	0.000261	0.00575	CbGeAlD
Sorafenib—HIPK3—vagina—colon cancer	0.000261	0.00574	CbGeAlD
Sorafenib—CDK7—liver—colon cancer	0.00026	0.00573	CbGeAlD
Sorafenib—TAOK2—liver—colon cancer	0.000258	0.00568	CbGeAlD
Sorafenib—FLT3—lymphoid tissue—colon cancer	0.000254	0.00559	CbGeAlD
Sorafenib—MKNK2—renal system—colon cancer	0.000252	0.00554	CbGeAlD
Sorafenib—RET—renal system—colon cancer	0.000245	0.0054	CbGeAlD
Sorafenib—BRAF—bone marrow—colon cancer	0.000244	0.00537	CbGeAlD
Sorafenib—KDR—embryo—colon cancer	0.000241	0.00531	CbGeAlD
Sorafenib—RALBP1—smooth muscle tissue—colon cancer	0.000236	0.0052	CbGeAlD
Sorafenib—CSF1R—embryo—colon cancer	0.000236	0.00519	CbGeAlD
Sorafenib—BRAF—vagina—colon cancer	0.000234	0.00514	CbGeAlD
Sorafenib—FLT1—epithelium—colon cancer	0.000233	0.00513	CbGeAlD
Sorafenib—RAF1—epithelium—colon cancer	0.000232	0.0051	CbGeAlD
Sorafenib—FLT3—bone marrow—colon cancer	0.000231	0.00509	CbGeAlD
Sorafenib—UGT1A9—digestive system—colon cancer	0.000231	0.00509	CbGeAlD
Sorafenib—FLT4—lymphoid tissue—colon cancer	0.000231	0.00508	CbGeAlD
Sorafenib—RALBP1—renal system—colon cancer	0.000227	0.005	CbGeAlD
Sorafenib—ZAK—liver—colon cancer	0.000225	0.00495	CbGeAlD
Sorafenib—Vismodegib—ABCB1—colon cancer	0.000225	0.11	CrCbGaD
Sorafenib—FLT1—smooth muscle tissue—colon cancer	0.000224	0.00494	CbGeAlD
Sorafenib—EPHX2—vagina—colon cancer	0.000223	0.00492	CbGeAlD
Sorafenib—RAF1—smooth muscle tissue—colon cancer	0.000223	0.00491	CbGeAlD
Sorafenib—HIPK3—liver—colon cancer	0.00022	0.00484	CbGeAlD
Sorafenib—FLT1—renal system—colon cancer	0.000216	0.00476	CbGeAlD
Sorafenib—RAF1—renal system—colon cancer	0.000215	0.00473	CbGeAlD
Sorafenib—KIT—embryo—colon cancer	0.000214	0.00471	CbGeAlD
Sorafenib—PDGFRA—smooth muscle tissue—colon cancer	0.00021	0.00463	CbGeAlD
Sorafenib—FLT4—bone marrow—colon cancer	0.00021	0.00463	CbGeAlD
Sorafenib—MKNK2—lymphoid tissue—colon cancer	0.000209	0.0046	CbGeAlD
Sorafenib—PDGFRB—embryo—colon cancer	0.000209	0.0046	CbGeAlD
Sorafenib—MKNK2—digestive system—colon cancer	0.000206	0.00454	CbGeAlD
Sorafenib—MKNK1—lymphoid tissue—colon cancer	0.000206	0.00454	CbGeAlD
Sorafenib—TIE1—liver—colon cancer	0.000206	0.00453	CbGeAlD
Sorafenib—STK10—renal system—colon cancer	0.000205	0.0045	CbGeAlD
Sorafenib—MKNK1—digestive system—colon cancer	0.000204	0.00449	CbGeAlD
Sorafenib—RET—lymphoid tissue—colon cancer	0.000204	0.00449	CbGeAlD
Sorafenib—MAPK11—lymph node—colon cancer	0.000203	0.00446	CbGeAlD
Sorafenib—PDGFRA—renal system—colon cancer	0.000202	0.00446	CbGeAlD
Sorafenib—RET—digestive system—colon cancer	0.000201	0.00443	CbGeAlD
Sorafenib—CDK7—lymph node—colon cancer	0.000199	0.00439	CbGeAlD
Sorafenib—FGFR1—vagina—colon cancer	0.000199	0.00437	CbGeAlD
Sorafenib—TAOK2—lymph node—colon cancer	0.000198	0.00435	CbGeAlD
Sorafenib—BRAF—liver—colon cancer	0.000197	0.00434	CbGeAlD
Sorafenib—KDR—epithelium—colon cancer	0.000197	0.00434	CbGeAlD
Sorafenib—MAP3K7—bone marrow—colon cancer	0.000196	0.00432	CbGeAlD
Sorafenib—AURKC—lymph node—colon cancer	0.000196	0.00432	CbGeAlD
Sorafenib—UGT1A1—renal system—colon cancer	0.000193	0.00425	CbGeAlD
Sorafenib—MKNK2—bone marrow—colon cancer	0.00019	0.00419	CbGeAlD
Sorafenib—KDR—smooth muscle tissue—colon cancer	0.00019	0.00418	CbGeAlD
Sorafenib—EPHX2—liver—colon cancer	0.000188	0.00415	CbGeAlD
Sorafenib—MAP3K7—vagina—colon cancer	0.000188	0.00414	CbGeAlD
Sorafenib—MKNK1—bone marrow—colon cancer	0.000188	0.00414	CbGeAlD
Sorafenib—FLT3—liver—colon cancer	0.000187	0.00412	CbGeAlD
Sorafenib—RALBP1—digestive system—colon cancer	0.000186	0.0041	CbGeAlD
Sorafenib—CSF1R—smooth muscle tissue—colon cancer	0.000185	0.00408	CbGeAlD
Sorafenib—KDR—renal system—colon cancer	0.000183	0.00402	CbGeAlD
Sorafenib—MKNK2—vagina—colon cancer	0.000182	0.00401	CbGeAlD
Sorafenib—MKNK1—vagina—colon cancer	0.00018	0.00396	CbGeAlD
Sorafenib—FLT1—lymphoid tissue—colon cancer	0.000179	0.00395	CbGeAlD
Sorafenib—RAF1—lymphoid tissue—colon cancer	0.000178	0.00393	CbGeAlD
Sorafenib—FLT1—digestive system—colon cancer	0.000177	0.0039	CbGeAlD
Sorafenib—RAF1—digestive system—colon cancer	0.000176	0.00388	CbGeAlD
Sorafenib—KIT—epithelium—colon cancer	0.000175	0.00384	CbGeAlD
Sorafenib—ZAK—lymph node—colon cancer	0.000172	0.00379	CbGeAlD
Sorafenib—UGT1A9—liver—colon cancer	0.000172	0.00379	CbGeAlD
Sorafenib—RALBP1—bone marrow—colon cancer	0.000172	0.00378	CbGeAlD
Sorafenib—PDGFRB—epithelium—colon cancer	0.00017	0.00375	CbGeAlD
Sorafenib—STK10—lymphoid tissue—colon cancer	0.00017	0.00374	CbGeAlD
Sorafenib—FLT4—liver—colon cancer	0.00017	0.00374	CbGeAlD
Sorafenib—HIPK3—lymph node—colon cancer	0.000169	0.00371	CbGeAlD
Sorafenib—KIT—smooth muscle tissue—colon cancer	0.000168	0.0037	CbGeAlD
Sorafenib—PDGFRA—lymphoid tissue—colon cancer	0.000168	0.0037	CbGeAlD
Sorafenib—STK10—digestive system—colon cancer	0.000168	0.00369	CbGeAlD
Sorafenib—FGFR1—liver—colon cancer	0.000168	0.00369	CbGeAlD
Sorafenib—PDGFRA—digestive system—colon cancer	0.000166	0.00366	CbGeAlD
Sorafenib—RALBP1—vagina—colon cancer	0.000165	0.00362	CbGeAlD
Sorafenib—PDGFRB—smooth muscle tissue—colon cancer	0.000164	0.00362	CbGeAlD
Sorafenib—RAF1—bone marrow—colon cancer	0.000162	0.00358	CbGeAlD
Sorafenib—KIT—renal system—colon cancer	0.000162	0.00356	CbGeAlD
Sorafenib—MAP3K7—liver—colon cancer	0.000159	0.00349	CbGeAlD
Sorafenib—UGT1A1—digestive system—colon cancer	0.000158	0.00349	CbGeAlD
Sorafenib—PDGFRB—renal system—colon cancer	0.000158	0.00348	CbGeAlD
Sorafenib—TIE1—lymph node—colon cancer	0.000158	0.00347	CbGeAlD
Sorafenib—FLT1—vagina—colon cancer	0.000157	0.00345	CbGeAlD
Sorafenib—RAF1—vagina—colon cancer	0.000156	0.00343	CbGeAlD
Sorafenib—EPHB6—vagina—colon cancer	0.000155	0.00341	CbGeAlD
Sorafenib—STK10—bone marrow—colon cancer	0.000155	0.00341	CbGeAlD
Sorafenib—MKNK2—liver—colon cancer	0.000154	0.00339	CbGeAlD
Sorafenib—MKNK1—liver—colon cancer	0.000152	0.00334	CbGeAlD
Sorafenib—KDR—lymphoid tissue—colon cancer	0.000152	0.00334	CbGeAlD
Sorafenib—BRAF—lymph node—colon cancer	0.000151	0.00333	CbGeAlD
Sorafenib—KDR—digestive system—colon cancer	0.00015	0.0033	CbGeAlD
Sorafenib—STK10—vagina—colon cancer	0.000148	0.00326	CbGeAlD
Sorafenib—CSF1R—lymphoid tissue—colon cancer	0.000148	0.00326	CbGeAlD
Sorafenib—PDGFRA—vagina—colon cancer	0.000147	0.00323	CbGeAlD
Sorafenib—CSF1R—digestive system—colon cancer	0.000146	0.00322	CbGeAlD
Sorafenib—EPHX2—lymph node—colon cancer	0.000144	0.00318	CbGeAlD
Sorafenib—FLT3—lymph node—colon cancer	0.000143	0.00316	CbGeAlD
Sorafenib—CYP3A7—liver—colon cancer	0.000143	0.00315	CbGeAlD
Sorafenib—RALBP1—liver—colon cancer	0.000139	0.00306	CbGeAlD
Sorafenib—KDR—bone marrow—colon cancer	0.000138	0.00304	CbGeAlD
Sorafenib—CSF1R—bone marrow—colon cancer	0.000135	0.00297	CbGeAlD
Sorafenib—KIT—lymphoid tissue—colon cancer	0.000134	0.00296	CbGeAlD
Sorafenib—KIT—digestive system—colon cancer	0.000133	0.00292	CbGeAlD
Sorafenib—MAP2K5—vagina—colon cancer	0.000132	0.00291	CbGeAlD
Sorafenib—KDR—vagina—colon cancer	0.000132	0.00291	CbGeAlD
Sorafenib—FLT1—liver—colon cancer	0.000132	0.00291	CbGeAlD
Sorafenib—PDGFRB—lymphoid tissue—colon cancer	0.000131	0.00289	CbGeAlD
Sorafenib—RAF1—liver—colon cancer	0.000131	0.00289	CbGeAlD
Sorafenib—FLT4—lymph node—colon cancer	0.00013	0.00287	CbGeAlD
Sorafenib—HTR2B—smooth muscle tissue—colon cancer	0.00013	0.00286	CbGeAlD
Sorafenib—PDGFRB—digestive system—colon cancer	0.00013	0.00286	CbGeAlD
Sorafenib—CSF1R—vagina—colon cancer	0.000129	0.00284	CbGeAlD
Sorafenib—FGFR1—lymph node—colon cancer	0.000128	0.00283	CbGeAlD
Sorafenib—ABCC4—renal system—colon cancer	0.000126	0.00277	CbGeAlD
Sorafenib—STK10—liver—colon cancer	0.000125	0.00275	CbGeAlD
Sorafenib—PDGFRA—liver—colon cancer	0.000124	0.00272	CbGeAlD
Sorafenib—KIT—bone marrow—colon cancer	0.000122	0.0027	CbGeAlD
Sorafenib—ABCC2—renal system—colon cancer	0.000122	0.00268	CbGeAlD
Sorafenib—CYP3A7-CYP3A51P—liver—colon cancer	0.000122	0.00268	CbGeAlD
Sorafenib—MAP3K7—lymph node—colon cancer	0.000122	0.00268	CbGeAlD
Sorafenib—PDGFRB—bone marrow—colon cancer	0.00012	0.00263	CbGeAlD
Sorafenib—UGT1A1—liver—colon cancer	0.000118	0.0026	CbGeAlD
Sorafenib—MKNK2—lymph node—colon cancer	0.000118	0.0026	CbGeAlD
Sorafenib—KIT—vagina—colon cancer	0.000117	0.00258	CbGeAlD
Sorafenib—MKNK1—lymph node—colon cancer	0.000116	0.00256	CbGeAlD
Sorafenib—RET—lymph node—colon cancer	0.000115	0.00253	CbGeAlD
Sorafenib—PDGFRB—vagina—colon cancer	0.000115	0.00252	CbGeAlD
Sorafenib—KDR—liver—colon cancer	0.000112	0.00246	CbGeAlD
Sorafenib—MAP2K5—liver—colon cancer	0.000112	0.00246	CbGeAlD
Sorafenib—CSF1R—liver—colon cancer	0.000109	0.0024	CbGeAlD
Sorafenib—RALBP1—lymph node—colon cancer	0.000106	0.00234	CbGeAlD
Sorafenib—Flushing—Irinotecan—colon cancer	0.000106	0.00206	CcSEcCtD
Sorafenib—Cardiac disorder—Irinotecan—colon cancer	0.000106	0.00206	CcSEcCtD
Sorafenib—Mediastinal disorder—Vincristine—colon cancer	0.000105	0.00205	CcSEcCtD
Sorafenib—Mood swings—Capecitabine—colon cancer	0.000104	0.00203	CcSEcCtD
Sorafenib—ABCC4—digestive system—colon cancer	0.000103	0.00227	CbGeAlD
Sorafenib—Alopecia—Vincristine—colon cancer	0.000103	0.00201	CcSEcCtD
Sorafenib—Angiopathy—Irinotecan—colon cancer	0.000103	0.00201	CcSEcCtD
Sorafenib—Immune system disorder—Irinotecan—colon cancer	0.000103	0.00201	CcSEcCtD
Sorafenib—HTR2B—digestive system—colon cancer	0.000103	0.00226	CbGeAlD
Sorafenib—Mediastinal disorder—Irinotecan—colon cancer	0.000103	0.002	CcSEcCtD
Sorafenib—Dehydration—Capecitabine—colon cancer	0.000102	0.002	CcSEcCtD
Sorafenib—Mental disorder—Vincristine—colon cancer	0.000102	0.002	CcSEcCtD
Sorafenib—Neoplasm—Methotrexate—colon cancer	0.000102	0.00199	CcSEcCtD
Sorafenib—Mouth ulceration—Methotrexate—colon cancer	0.000102	0.00199	CcSEcCtD
Sorafenib—Arrhythmia—Irinotecan—colon cancer	0.000102	0.00198	CcSEcCtD
Sorafenib—FLT1—lymph node—colon cancer	0.000101	0.00223	CbGeAlD
Sorafenib—Gynaecomastia—Methotrexate—colon cancer	0.000101	0.00197	CcSEcCtD
Sorafenib—Dry skin—Capecitabine—colon cancer	0.000101	0.00197	CcSEcCtD
Sorafenib—RAF1—lymph node—colon cancer	0.000101	0.00222	CbGeAlD
Sorafenib—Alopecia—Irinotecan—colon cancer	0.000101	0.00196	CcSEcCtD
Sorafenib—Abdominal pain upper—Capecitabine—colon cancer	0.000101	0.00196	CcSEcCtD
Sorafenib—Hypokalaemia—Capecitabine—colon cancer	0.0001	0.00195	CcSEcCtD
Sorafenib—EPHB6—lymph node—colon cancer	0.0001	0.0022	CbGeAlD
Sorafenib—ABCC2—digestive system—colon cancer	9.99e-05	0.0022	CbGeAlD
Sorafenib—Breast disorder—Capecitabine—colon cancer	9.95e-05	0.00194	CcSEcCtD
Sorafenib—Aspartate aminotransferase increased—Capecitabine—colon cancer	9.91e-05	0.00193	CcSEcCtD
Sorafenib—Toxic epidermal necrolysis—Capecitabine—colon cancer	9.91e-05	0.00193	CcSEcCtD
Sorafenib—KIT—liver—colon cancer	9.89e-05	0.00218	CbGeAlD
Sorafenib—Nasopharyngitis—Capecitabine—colon cancer	9.84e-05	0.00192	CcSEcCtD
Sorafenib—Gastritis—Capecitabine—colon cancer	9.74e-05	0.0019	CcSEcCtD
Sorafenib—Arrhythmia—Fluorouracil—colon cancer	9.74e-05	0.0019	CcSEcCtD
Sorafenib—Alanine aminotransferase increased—Capecitabine—colon cancer	9.71e-05	0.00189	CcSEcCtD
Sorafenib—ABCB1—blood vessel—colon cancer	9.71e-05	0.00214	CbGeAlD
Sorafenib—PDGFRB—liver—colon cancer	9.66e-05	0.00213	CbGeAlD
Sorafenib—Alopecia—Fluorouracil—colon cancer	9.63e-05	0.00188	CcSEcCtD
Sorafenib—STK10—lymph node—colon cancer	9.58e-05	0.00211	CbGeAlD
Sorafenib—Muscle spasms—Irinotecan—colon cancer	9.52e-05	0.00186	CcSEcCtD
Sorafenib—ABCC4—bone marrow—colon cancer	9.52e-05	0.0021	CbGeAlD
Sorafenib—Dysphagia—Capecitabine—colon cancer	9.52e-05	0.00186	CcSEcCtD
Sorafenib—Erythema—Fluorouracil—colon cancer	9.49e-05	0.00185	CcSEcCtD
Sorafenib—PDGFRA—lymph node—colon cancer	9.49e-05	0.00209	CbGeAlD
Sorafenib—Anaemia—Vincristine—colon cancer	9.4e-05	0.00183	CcSEcCtD
Sorafenib—Anaemia—Irinotecan—colon cancer	9.16e-05	0.00179	CcSEcCtD
Sorafenib—CYP2C8—renal system—colon cancer	9.14e-05	0.00201	CbGeAlD
Sorafenib—Abdominal discomfort—Capecitabine—colon cancer	9.12e-05	0.00178	CcSEcCtD
Sorafenib—Hepatic failure—Methotrexate—colon cancer	9.12e-05	0.00178	CcSEcCtD
Sorafenib—Leukopenia—Vincristine—colon cancer	9.1e-05	0.00178	CcSEcCtD
Sorafenib—HTR2B—vagina—colon cancer	9.07e-05	0.002	CbGeAlD
Sorafenib—Neutropenia—Capecitabine—colon cancer	8.9e-05	0.00174	CcSEcCtD
Sorafenib—Syncope—Irinotecan—colon cancer	8.88e-05	0.00173	CcSEcCtD
Sorafenib—Renal failure acute—Methotrexate—colon cancer	8.88e-05	0.00173	CcSEcCtD
Sorafenib—Leukopenia—Irinotecan—colon cancer	8.87e-05	0.00173	CcSEcCtD
Sorafenib—Hypertension—Vincristine—colon cancer	8.78e-05	0.00171	CcSEcCtD
Sorafenib—Anaemia—Fluorouracil—colon cancer	8.77e-05	0.00171	CcSEcCtD
Sorafenib—Loss of consciousness—Irinotecan—colon cancer	8.71e-05	0.0017	CcSEcCtD
Sorafenib—Dermatitis exfoliative—Methotrexate—colon cancer	8.69e-05	0.00169	CcSEcCtD
Sorafenib—Myalgia—Vincristine—colon cancer	8.66e-05	0.00169	CcSEcCtD
Sorafenib—Cough—Irinotecan—colon cancer	8.64e-05	0.00169	CcSEcCtD
Sorafenib—Weight decreased—Capecitabine—colon cancer	8.61e-05	0.00168	CcSEcCtD
Sorafenib—CYP2C19—digestive system—colon cancer	8.59e-05	0.00189	CbGeAlD
Sorafenib—MAP2K5—lymph node—colon cancer	8.56e-05	0.00188	CbGeAlD
Sorafenib—KDR—lymph node—colon cancer	8.56e-05	0.00188	CbGeAlD
Sorafenib—CYP1A2—renal system—colon cancer	8.55e-05	0.00188	CbGeAlD
Sorafenib—Hypertension—Irinotecan—colon cancer	8.55e-05	0.00167	CcSEcCtD
Sorafenib—Pneumonia—Capecitabine—colon cancer	8.53e-05	0.00166	CcSEcCtD
Sorafenib—Leukopenia—Fluorouracil—colon cancer	8.49e-05	0.00166	CcSEcCtD
Sorafenib—Infestation—Capecitabine—colon cancer	8.48e-05	0.00166	CcSEcCtD
Sorafenib—Infestation NOS—Capecitabine—colon cancer	8.48e-05	0.00166	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Capecitabine—colon cancer	8.41e-05	0.00164	CcSEcCtD
Sorafenib—Acute coronary syndrome—Capecitabine—colon cancer	8.36e-05	0.00163	CcSEcCtD
Sorafenib—CSF1R—lymph node—colon cancer	8.35e-05	0.00184	CbGeAlD
Sorafenib—Renal failure—Capecitabine—colon cancer	8.34e-05	0.00163	CcSEcCtD
Sorafenib—Neuropathy peripheral—Capecitabine—colon cancer	8.32e-05	0.00162	CcSEcCtD
Sorafenib—Myocardial infarction—Capecitabine—colon cancer	8.32e-05	0.00162	CcSEcCtD
Sorafenib—Anaphylactic shock—Vincristine—colon cancer	8.3e-05	0.00162	CcSEcCtD
Sorafenib—Jaundice—Capecitabine—colon cancer	8.27e-05	0.00161	CcSEcCtD
Sorafenib—Stomatitis—Capecitabine—colon cancer	8.27e-05	0.00161	CcSEcCtD
Sorafenib—CYP3A5—renal system—colon cancer	8.25e-05	0.00182	CbGeAlD
Sorafenib—Infection—Vincristine—colon cancer	8.25e-05	0.00161	CcSEcCtD
Sorafenib—CYP2B6—renal system—colon cancer	8.2e-05	0.00181	CbGeAlD
Sorafenib—Nervous system disorder—Vincristine—colon cancer	8.14e-05	0.00159	CcSEcCtD
Sorafenib—Thrombocytopenia—Vincristine—colon cancer	8.13e-05	0.00159	CcSEcCtD
Sorafenib—Anaphylactic shock—Irinotecan—colon cancer	8.08e-05	0.00158	CcSEcCtD
Sorafenib—Myalgia—Fluorouracil—colon cancer	8.08e-05	0.00158	CcSEcCtD
Sorafenib—Infection—Irinotecan—colon cancer	8.03e-05	0.00157	CcSEcCtD
Sorafenib—Hepatobiliary disease—Capecitabine—colon cancer	8.02e-05	0.00157	CcSEcCtD
Sorafenib—Epistaxis—Capecitabine—colon cancer	8e-05	0.00156	CcSEcCtD
Sorafenib—Shock—Irinotecan—colon cancer	7.95e-05	0.00155	CcSEcCtD
Sorafenib—Nervous system disorder—Irinotecan—colon cancer	7.93e-05	0.00155	CcSEcCtD
Sorafenib—Thrombocytopenia—Irinotecan—colon cancer	7.92e-05	0.00154	CcSEcCtD
Sorafenib—Anorexia—Vincristine—colon cancer	7.91e-05	0.00154	CcSEcCtD
Sorafenib—Mood swings—Methotrexate—colon cancer	7.76e-05	0.00151	CcSEcCtD
Sorafenib—Anaphylactic shock—Fluorouracil—colon cancer	7.74e-05	0.00151	CcSEcCtD
Sorafenib—Anorexia—Irinotecan—colon cancer	7.71e-05	0.0015	CcSEcCtD
Sorafenib—Infection—Fluorouracil—colon cancer	7.69e-05	0.0015	CcSEcCtD
Sorafenib—ABCC4—liver—colon cancer	7.69e-05	0.00169	CbGeAlD
Sorafenib—Haemoglobin—Capecitabine—colon cancer	7.65e-05	0.00149	CcSEcCtD
Sorafenib—Haemorrhage—Capecitabine—colon cancer	7.62e-05	0.00149	CcSEcCtD
Sorafenib—Nervous system disorder—Fluorouracil—colon cancer	7.59e-05	0.00148	CcSEcCtD
Sorafenib—CYP2C19—vagina—colon cancer	7.58e-05	0.00167	CbGeAlD
Sorafenib—KIT—lymph node—colon cancer	7.58e-05	0.00167	CbGeAlD
Sorafenib—Thrombocytopenia—Fluorouracil—colon cancer	7.58e-05	0.00148	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Vincristine—colon cancer	7.56e-05	0.00148	CcSEcCtD
Sorafenib—Urinary tract disorder—Capecitabine—colon cancer	7.52e-05	0.00147	CcSEcCtD
Sorafenib—Connective tissue disorder—Capecitabine—colon cancer	7.48e-05	0.00146	CcSEcCtD
Sorafenib—Urethral disorder—Capecitabine—colon cancer	7.47e-05	0.00146	CcSEcCtD
Sorafenib—ABCC2—liver—colon cancer	7.45e-05	0.00164	CbGeAlD
Sorafenib—PDGFRB—lymph node—colon cancer	7.41e-05	0.00163	CbGeAlD
Sorafenib—Breast disorder—Methotrexate—colon cancer	7.41e-05	0.00145	CcSEcCtD
Sorafenib—Anorexia—Fluorouracil—colon cancer	7.38e-05	0.00144	CcSEcCtD
Sorafenib—Toxic epidermal necrolysis—Methotrexate—colon cancer	7.38e-05	0.00144	CcSEcCtD
Sorafenib—Decreased appetite—Vincristine—colon cancer	7.22e-05	0.00141	CcSEcCtD
Sorafenib—Dyspnoea—Irinotecan—colon cancer	7.21e-05	0.00141	CcSEcCtD
Sorafenib—Erythema multiforme—Capecitabine—colon cancer	7.2e-05	0.00141	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Vincristine—colon cancer	7.17e-05	0.0014	CcSEcCtD
Sorafenib—Fatigue—Vincristine—colon cancer	7.16e-05	0.0014	CcSEcCtD
Sorafenib—Dyspepsia—Irinotecan—colon cancer	7.12e-05	0.00139	CcSEcCtD
Sorafenib—Tinnitus—Capecitabine—colon cancer	7.1e-05	0.00139	CcSEcCtD
Sorafenib—Constipation—Vincristine—colon cancer	7.1e-05	0.00139	CcSEcCtD
Sorafenib—Pain—Vincristine—colon cancer	7.1e-05	0.00139	CcSEcCtD
Sorafenib—Cardiac disorder—Capecitabine—colon cancer	7.07e-05	0.00138	CcSEcCtD
Sorafenib—Flushing—Capecitabine—colon cancer	7.07e-05	0.00138	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Fluorouracil—colon cancer	7.05e-05	0.00138	CcSEcCtD
Sorafenib—Decreased appetite—Irinotecan—colon cancer	7.03e-05	0.00137	CcSEcCtD
Sorafenib—CYP1A2—digestive system—colon cancer	7.01e-05	0.00154	CbGeAlD
Sorafenib—Gastrointestinal disorder—Irinotecan—colon cancer	6.98e-05	0.00136	CcSEcCtD
Sorafenib—Fatigue—Irinotecan—colon cancer	6.97e-05	0.00136	CcSEcCtD
Sorafenib—Pancreatitis—Methotrexate—colon cancer	6.94e-05	0.00136	CcSEcCtD
Sorafenib—Pain—Irinotecan—colon cancer	6.91e-05	0.00135	CcSEcCtD
Sorafenib—Constipation—Irinotecan—colon cancer	6.91e-05	0.00135	CcSEcCtD
Sorafenib—Angiopathy—Capecitabine—colon cancer	6.91e-05	0.00135	CcSEcCtD
Sorafenib—Dyspnoea—Fluorouracil—colon cancer	6.9e-05	0.00135	CcSEcCtD
Sorafenib—Immune system disorder—Capecitabine—colon cancer	6.88e-05	0.00134	CcSEcCtD
Sorafenib—Mediastinal disorder—Capecitabine—colon cancer	6.86e-05	0.00134	CcSEcCtD
Sorafenib—Dyspepsia—Fluorouracil—colon cancer	6.82e-05	0.00133	CcSEcCtD
Sorafenib—CYP2B6—lymphoid tissue—colon cancer	6.81e-05	0.0015	CbGeAlD
Sorafenib—Arrhythmia—Capecitabine—colon cancer	6.8e-05	0.00133	CcSEcCtD
Sorafenib—Abdominal discomfort—Methotrexate—colon cancer	6.79e-05	0.00132	CcSEcCtD
Sorafenib—Gastrointestinal pain—Vincristine—colon cancer	6.79e-05	0.00132	CcSEcCtD
Sorafenib—CYP3A5—digestive system—colon cancer	6.77e-05	0.00149	CbGeAlD
Sorafenib—Decreased appetite—Fluorouracil—colon cancer	6.73e-05	0.00131	CcSEcCtD
Sorafenib—Alopecia—Capecitabine—colon cancer	6.73e-05	0.00131	CcSEcCtD
Sorafenib—CYP2B6—digestive system—colon cancer	6.72e-05	0.00148	CbGeAlD
Sorafenib—ABCG2—bone marrow—colon cancer	6.72e-05	0.00148	CbGeAlD
Sorafenib—Gastrointestinal disorder—Fluorouracil—colon cancer	6.68e-05	0.0013	CcSEcCtD
Sorafenib—Mental disorder—Capecitabine—colon cancer	6.67e-05	0.0013	CcSEcCtD
Sorafenib—CYP2C9—digestive system—colon cancer	6.66e-05	0.00147	CbGeAlD
Sorafenib—Malnutrition—Capecitabine—colon cancer	6.63e-05	0.00129	CcSEcCtD
Sorafenib—Erythema—Capecitabine—colon cancer	6.63e-05	0.00129	CcSEcCtD
Sorafenib—Neutropenia—Methotrexate—colon cancer	6.62e-05	0.00129	CcSEcCtD
Sorafenib—Pain—Fluorouracil—colon cancer	6.62e-05	0.00129	CcSEcCtD
Sorafenib—CYP2C8—vagina—colon cancer	6.62e-05	0.00146	CbGeAlD
Sorafenib—Gastrointestinal pain—Irinotecan—colon cancer	6.61e-05	0.00129	CcSEcCtD
Sorafenib—Abdominal pain—Vincristine—colon cancer	6.56e-05	0.00128	CcSEcCtD
Sorafenib—Body temperature increased—Vincristine—colon cancer	6.56e-05	0.00128	CcSEcCtD
Sorafenib—Erectile dysfunction—Methotrexate—colon cancer	6.52e-05	0.00127	CcSEcCtD
Sorafenib—Dysgeusia—Capecitabine—colon cancer	6.49e-05	0.00127	CcSEcCtD
Sorafenib—ABCG2—vagina—colon cancer	6.44e-05	0.00142	CbGeAlD
Sorafenib—CYP2C19—liver—colon cancer	6.4e-05	0.00141	CbGeAlD
Sorafenib—Abdominal pain—Irinotecan—colon cancer	6.39e-05	0.00125	CcSEcCtD
Sorafenib—Body temperature increased—Irinotecan—colon cancer	6.39e-05	0.00125	CcSEcCtD
Sorafenib—Muscle spasms—Capecitabine—colon cancer	6.37e-05	0.00124	CcSEcCtD
Sorafenib—Pneumonia—Methotrexate—colon cancer	6.35e-05	0.00124	CcSEcCtD
Sorafenib—Infestation NOS—Methotrexate—colon cancer	6.32e-05	0.00123	CcSEcCtD
Sorafenib—Infestation—Methotrexate—colon cancer	6.32e-05	0.00123	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Methotrexate—colon cancer	6.26e-05	0.00122	CcSEcCtD
Sorafenib—Renal failure—Methotrexate—colon cancer	6.21e-05	0.00121	CcSEcCtD
Sorafenib—CYP3A4—renal system—colon cancer	6.19e-05	0.00136	CbGeAlD
Sorafenib—Stomatitis—Methotrexate—colon cancer	6.16e-05	0.0012	CcSEcCtD
Sorafenib—Urticaria—Fluorouracil—colon cancer	6.15e-05	0.0012	CcSEcCtD
Sorafenib—Anaemia—Capecitabine—colon cancer	6.13e-05	0.0012	CcSEcCtD
Sorafenib—Body temperature increased—Fluorouracil—colon cancer	6.12e-05	0.00119	CcSEcCtD
Sorafenib—Hypersensitivity—Vincristine—colon cancer	6.12e-05	0.00119	CcSEcCtD
Sorafenib—CYP2D6—renal system—colon cancer	6.09e-05	0.00134	CbGeAlD
Sorafenib—CYP3A5—vagina—colon cancer	5.97e-05	0.00132	CbGeAlD
Sorafenib—Hepatobiliary disease—Methotrexate—colon cancer	5.97e-05	0.00117	CcSEcCtD
Sorafenib—Epistaxis—Methotrexate—colon cancer	5.96e-05	0.00116	CcSEcCtD
Sorafenib—Hypersensitivity—Irinotecan—colon cancer	5.96e-05	0.00116	CcSEcCtD
Sorafenib—Asthenia—Vincristine—colon cancer	5.96e-05	0.00116	CcSEcCtD
Sorafenib—Syncope—Capecitabine—colon cancer	5.95e-05	0.00116	CcSEcCtD
Sorafenib—CYP2B6—vagina—colon cancer	5.94e-05	0.00131	CbGeAlD
Sorafenib—Leukopenia—Capecitabine—colon cancer	5.93e-05	0.00116	CcSEcCtD
Sorafenib—ABCC4—lymph node—colon cancer	5.9e-05	0.0013	CbGeAlD
Sorafenib—HTR2B—lymph node—colon cancer	5.87e-05	0.00129	CbGeAlD
Sorafenib—Loss of consciousness—Capecitabine—colon cancer	5.83e-05	0.00114	CcSEcCtD
Sorafenib—Asthenia—Irinotecan—colon cancer	5.8e-05	0.00113	CcSEcCtD
Sorafenib—ABCB1—embryo—colon cancer	5.79e-05	0.00127	CbGeAlD
Sorafenib—Cough—Capecitabine—colon cancer	5.79e-05	0.00113	CcSEcCtD
Sorafenib—Hypertension—Capecitabine—colon cancer	5.72e-05	0.00112	CcSEcCtD
Sorafenib—ABCC2—lymph node—colon cancer	5.71e-05	0.00126	CbGeAlD
Sorafenib—Hypersensitivity—Fluorouracil—colon cancer	5.7e-05	0.00111	CcSEcCtD
Sorafenib—Haemoglobin—Methotrexate—colon cancer	5.7e-05	0.00111	CcSEcCtD
Sorafenib—Diarrhoea—Vincristine—colon cancer	5.68e-05	0.00111	CcSEcCtD
Sorafenib—Haemorrhage—Methotrexate—colon cancer	5.67e-05	0.00111	CcSEcCtD
Sorafenib—Arthralgia—Capecitabine—colon cancer	5.64e-05	0.0011	CcSEcCtD
Sorafenib—Myalgia—Capecitabine—colon cancer	5.64e-05	0.0011	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	5.61e-05	0.00109	CcSEcCtD
Sorafenib—Urinary tract disorder—Methotrexate—colon cancer	5.6e-05	0.00109	CcSEcCtD
Sorafenib—CYP2C8—liver—colon cancer	5.58e-05	0.00123	CbGeAlD
Sorafenib—Urethral disorder—Methotrexate—colon cancer	5.56e-05	0.00108	CcSEcCtD
Sorafenib—Diarrhoea—Irinotecan—colon cancer	5.53e-05	0.00108	CcSEcCtD
Sorafenib—Dry mouth—Capecitabine—colon cancer	5.52e-05	0.00108	CcSEcCtD
Sorafenib—Dizziness—Vincristine—colon cancer	5.49e-05	0.00107	CcSEcCtD
Sorafenib—Pruritus—Fluorouracil—colon cancer	5.48e-05	0.00107	CcSEcCtD
Sorafenib—ABCG2—liver—colon cancer	5.43e-05	0.0012	CbGeAlD
Sorafenib—Infection—Capecitabine—colon cancer	5.38e-05	0.00105	CcSEcCtD
Sorafenib—Erythema multiforme—Methotrexate—colon cancer	5.36e-05	0.00105	CcSEcCtD
Sorafenib—Dizziness—Irinotecan—colon cancer	5.35e-05	0.00104	CcSEcCtD
Sorafenib—Shock—Capecitabine—colon cancer	5.32e-05	0.00104	CcSEcCtD
Sorafenib—Nervous system disorder—Capecitabine—colon cancer	5.31e-05	0.00104	CcSEcCtD
Sorafenib—Diarrhoea—Fluorouracil—colon cancer	5.3e-05	0.00103	CcSEcCtD
Sorafenib—Thrombocytopenia—Capecitabine—colon cancer	5.3e-05	0.00103	CcSEcCtD
Sorafenib—Tinnitus—Methotrexate—colon cancer	5.29e-05	0.00103	CcSEcCtD
Sorafenib—Vomiting—Vincristine—colon cancer	5.28e-05	0.00103	CcSEcCtD
Sorafenib—Cardiac disorder—Methotrexate—colon cancer	5.26e-05	0.00103	CcSEcCtD
Sorafenib—Skin disorder—Capecitabine—colon cancer	5.26e-05	0.00103	CcSEcCtD
Sorafenib—Rash—Vincristine—colon cancer	5.23e-05	0.00102	CcSEcCtD
Sorafenib—Dermatitis—Vincristine—colon cancer	5.23e-05	0.00102	CcSEcCtD
Sorafenib—CYP1A2—liver—colon cancer	5.23e-05	0.00115	CbGeAlD
Sorafenib—Headache—Vincristine—colon cancer	5.2e-05	0.00101	CcSEcCtD
Sorafenib—Anorexia—Capecitabine—colon cancer	5.16e-05	0.00101	CcSEcCtD
Sorafenib—Angiopathy—Methotrexate—colon cancer	5.14e-05	0.001	CcSEcCtD
Sorafenib—Vomiting—Irinotecan—colon cancer	5.14e-05	0.001	CcSEcCtD
Sorafenib—Immune system disorder—Methotrexate—colon cancer	5.12e-05	0.000999	CcSEcCtD
Sorafenib—Dizziness—Fluorouracil—colon cancer	5.12e-05	0.000999	CcSEcCtD
Sorafenib—Mediastinal disorder—Methotrexate—colon cancer	5.11e-05	0.000997	CcSEcCtD
Sorafenib—Rash—Irinotecan—colon cancer	5.1e-05	0.000995	CcSEcCtD
Sorafenib—Dermatitis—Irinotecan—colon cancer	5.09e-05	0.000994	CcSEcCtD
Sorafenib—CYP3A4—digestive system—colon cancer	5.08e-05	0.00112	CbGeAlD
Sorafenib—Headache—Irinotecan—colon cancer	5.06e-05	0.000988	CcSEcCtD
Sorafenib—CYP3A5—liver—colon cancer	5.04e-05	0.00111	CbGeAlD
Sorafenib—Alopecia—Methotrexate—colon cancer	5.01e-05	0.000978	CcSEcCtD
Sorafenib—CYP2B6—liver—colon cancer	5.01e-05	0.0011	CbGeAlD
Sorafenib—CYP2D6—digestive system—colon cancer	5e-05	0.0011	CbGeAlD
Sorafenib—Mental disorder—Methotrexate—colon cancer	4.97e-05	0.000969	CcSEcCtD
Sorafenib—CYP2C9—liver—colon cancer	4.96e-05	0.00109	CbGeAlD
Sorafenib—Erythema—Methotrexate—colon cancer	4.94e-05	0.000963	CcSEcCtD
Sorafenib—Malnutrition—Methotrexate—colon cancer	4.94e-05	0.000963	CcSEcCtD
Sorafenib—Nausea—Vincristine—colon cancer	4.93e-05	0.000962	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Capecitabine—colon cancer	4.93e-05	0.000962	CcSEcCtD
Sorafenib—Vomiting—Fluorouracil—colon cancer	4.92e-05	0.000961	CcSEcCtD
Sorafenib—Rash—Fluorouracil—colon cancer	4.88e-05	0.000953	CcSEcCtD
Sorafenib—Dermatitis—Fluorouracil—colon cancer	4.88e-05	0.000952	CcSEcCtD
Sorafenib—Headache—Fluorouracil—colon cancer	4.85e-05	0.000946	CcSEcCtD
Sorafenib—Dysgeusia—Methotrexate—colon cancer	4.83e-05	0.000943	CcSEcCtD
Sorafenib—Dyspnoea—Capecitabine—colon cancer	4.82e-05	0.000941	CcSEcCtD
Sorafenib—Nausea—Irinotecan—colon cancer	4.8e-05	0.000937	CcSEcCtD
Sorafenib—Dyspepsia—Capecitabine—colon cancer	4.76e-05	0.000929	CcSEcCtD
Sorafenib—ABCB1—epithelium—colon cancer	4.72e-05	0.00104	CbGeAlD
Sorafenib—Decreased appetite—Capecitabine—colon cancer	4.7e-05	0.000918	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Capecitabine—colon cancer	4.67e-05	0.000911	CcSEcCtD
Sorafenib—Fatigue—Capecitabine—colon cancer	4.67e-05	0.00091	CcSEcCtD
Sorafenib—Pain—Capecitabine—colon cancer	4.63e-05	0.000903	CcSEcCtD
Sorafenib—Constipation—Capecitabine—colon cancer	4.63e-05	0.000903	CcSEcCtD
Sorafenib—Nausea—Fluorouracil—colon cancer	4.6e-05	0.000897	CcSEcCtD
Sorafenib—Anaemia—Methotrexate—colon cancer	4.56e-05	0.00089	CcSEcCtD
Sorafenib—Gastrointestinal pain—Capecitabine—colon cancer	4.42e-05	0.000863	CcSEcCtD
Sorafenib—Leukopenia—Methotrexate—colon cancer	4.42e-05	0.000862	CcSEcCtD
Sorafenib—ABCB1—renal system—colon cancer	4.38e-05	0.000965	CbGeAlD
Sorafenib—Cough—Methotrexate—colon cancer	4.31e-05	0.00084	CcSEcCtD
Sorafenib—Urticaria—Capecitabine—colon cancer	4.3e-05	0.000839	CcSEcCtD
Sorafenib—Abdominal pain—Capecitabine—colon cancer	4.28e-05	0.000835	CcSEcCtD
Sorafenib—Body temperature increased—Capecitabine—colon cancer	4.28e-05	0.000835	CcSEcCtD
Sorafenib—Myalgia—Methotrexate—colon cancer	4.2e-05	0.00082	CcSEcCtD
Sorafenib—Arthralgia—Methotrexate—colon cancer	4.2e-05	0.00082	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	4.17e-05	0.000814	CcSEcCtD
Sorafenib—ABCG2—lymph node—colon cancer	4.16e-05	0.000917	CbGeAlD
Sorafenib—Anaphylactic shock—Methotrexate—colon cancer	4.03e-05	0.000786	CcSEcCtD
Sorafenib—Infection—Methotrexate—colon cancer	4e-05	0.000781	CcSEcCtD
Sorafenib—Hypersensitivity—Capecitabine—colon cancer	3.99e-05	0.000778	CcSEcCtD
Sorafenib—Nervous system disorder—Methotrexate—colon cancer	3.95e-05	0.000771	CcSEcCtD
Sorafenib—Thrombocytopenia—Methotrexate—colon cancer	3.94e-05	0.00077	CcSEcCtD
Sorafenib—Skin disorder—Methotrexate—colon cancer	3.91e-05	0.000763	CcSEcCtD
Sorafenib—Asthenia—Capecitabine—colon cancer	3.88e-05	0.000757	CcSEcCtD
Sorafenib—Anorexia—Methotrexate—colon cancer	3.84e-05	0.000749	CcSEcCtD
Sorafenib—Pruritus—Capecitabine—colon cancer	3.83e-05	0.000747	CcSEcCtD
Sorafenib—CYP3A4—liver—colon cancer	3.78e-05	0.000833	CbGeAlD
Sorafenib—CYP2D6—liver—colon cancer	3.72e-05	0.00082	CbGeAlD
Sorafenib—Diarrhoea—Capecitabine—colon cancer	3.7e-05	0.000722	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Methotrexate—colon cancer	3.67e-05	0.000716	CcSEcCtD
Sorafenib—ABCB1—lymphoid tissue—colon cancer	3.64e-05	0.000801	CbGeAlD
Sorafenib—ABCB1—digestive system—colon cancer	3.59e-05	0.000791	CbGeAlD
Sorafenib—Dyspnoea—Methotrexate—colon cancer	3.59e-05	0.000701	CcSEcCtD
Sorafenib—Dizziness—Capecitabine—colon cancer	3.58e-05	0.000698	CcSEcCtD
Sorafenib—Dyspepsia—Methotrexate—colon cancer	3.55e-05	0.000692	CcSEcCtD
Sorafenib—Decreased appetite—Methotrexate—colon cancer	3.5e-05	0.000683	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Methotrexate—colon cancer	3.48e-05	0.000679	CcSEcCtD
Sorafenib—Fatigue—Methotrexate—colon cancer	3.47e-05	0.000678	CcSEcCtD
Sorafenib—Pain—Methotrexate—colon cancer	3.44e-05	0.000672	CcSEcCtD
Sorafenib—Vomiting—Capecitabine—colon cancer	3.44e-05	0.000671	CcSEcCtD
Sorafenib—Rash—Capecitabine—colon cancer	3.41e-05	0.000666	CcSEcCtD
Sorafenib—Dermatitis—Capecitabine—colon cancer	3.41e-05	0.000665	CcSEcCtD
Sorafenib—Headache—Capecitabine—colon cancer	3.39e-05	0.000661	CcSEcCtD
Sorafenib—ABCB1—bone marrow—colon cancer	3.31e-05	0.00073	CbGeAlD
Sorafenib—Gastrointestinal pain—Methotrexate—colon cancer	3.29e-05	0.000643	CcSEcCtD
Sorafenib—Nausea—Capecitabine—colon cancer	3.21e-05	0.000627	CcSEcCtD
Sorafenib—Urticaria—Methotrexate—colon cancer	3.2e-05	0.000624	CcSEcCtD
Sorafenib—Abdominal pain—Methotrexate—colon cancer	3.18e-05	0.000621	CcSEcCtD
Sorafenib—Body temperature increased—Methotrexate—colon cancer	3.18e-05	0.000621	CcSEcCtD
Sorafenib—ABCB1—vagina—colon cancer	3.17e-05	0.000699	CbGeAlD
Sorafenib—Hypersensitivity—Methotrexate—colon cancer	2.97e-05	0.000579	CcSEcCtD
Sorafenib—Asthenia—Methotrexate—colon cancer	2.89e-05	0.000564	CcSEcCtD
Sorafenib—Pruritus—Methotrexate—colon cancer	2.85e-05	0.000556	CcSEcCtD
Sorafenib—Diarrhoea—Methotrexate—colon cancer	2.76e-05	0.000538	CcSEcCtD
Sorafenib—ABCB1—liver—colon cancer	2.68e-05	0.00059	CbGeAlD
Sorafenib—Dizziness—Methotrexate—colon cancer	2.66e-05	0.00052	CcSEcCtD
Sorafenib—Vomiting—Methotrexate—colon cancer	2.56e-05	0.0005	CcSEcCtD
Sorafenib—Rash—Methotrexate—colon cancer	2.54e-05	0.000496	CcSEcCtD
Sorafenib—Dermatitis—Methotrexate—colon cancer	2.54e-05	0.000495	CcSEcCtD
Sorafenib—Headache—Methotrexate—colon cancer	2.52e-05	0.000492	CcSEcCtD
Sorafenib—Nausea—Methotrexate—colon cancer	2.39e-05	0.000467	CcSEcCtD
Sorafenib—ABCB1—lymph node—colon cancer	2.05e-05	0.000452	CbGeAlD
Sorafenib—PDGFRB—Immune System—PIK3CA—colon cancer	1.37e-06	2.07e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—SRC—colon cancer	1.37e-06	2.06e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—SRC—colon cancer	1.37e-06	2.06e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—MYC—colon cancer	1.36e-06	2.05e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ABCB1—colon cancer	1.36e-06	2.04e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TGFB1—colon cancer	1.36e-06	2.04e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—MYC—colon cancer	1.35e-06	2.03e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TGFB1—colon cancer	1.34e-06	2.02e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—PIK3CA—colon cancer	1.34e-06	2.02e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PTGS2—colon cancer	1.34e-06	2.02e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—PIK3CA—colon cancer	1.34e-06	2.02e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CASP3—colon cancer	1.34e-06	2.02e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—EP300—colon cancer	1.33e-06	2.01e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—AKT1—colon cancer	1.33e-06	2.01e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—TYMS—colon cancer	1.33e-06	2.01e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—VEGFA—colon cancer	1.33e-06	2.01e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—VEGFA—colon cancer	1.33e-06	2.01e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TP53—colon cancer	1.33e-06	2.01e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—EGFR—colon cancer	1.33e-06	2e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—EP300—colon cancer	1.33e-06	2e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—KRAS—colon cancer	1.33e-06	2e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—MYC—colon cancer	1.33e-06	2e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—EGFR—colon cancer	1.33e-06	2e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PTGS2—colon cancer	1.33e-06	2e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—TGFB1—colon cancer	1.33e-06	2e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—HRAS—colon cancer	1.32e-06	2e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—EGFR—colon cancer	1.32e-06	1.98e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—NRAS—colon cancer	1.32e-06	1.98e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—NRAS—colon cancer	1.32e-06	1.98e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—AKT1—colon cancer	1.31e-06	1.98e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—AKT1—colon cancer	1.31e-06	1.98e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—EP300—colon cancer	1.31e-06	1.98e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—EP300—colon cancer	1.31e-06	1.98e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—HRAS—colon cancer	1.3e-06	1.96e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CCND1—colon cancer	1.3e-06	1.96e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—EGFR—colon cancer	1.3e-06	1.96e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—HRAS—colon cancer	1.3e-06	1.96e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—TYMS—colon cancer	1.3e-06	1.96e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.3e-06	1.96e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TP53—colon cancer	1.3e-06	1.95e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—SRC—colon cancer	1.3e-06	1.95e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—SRC—colon cancer	1.29e-06	1.95e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CTNNB1—colon cancer	1.29e-06	1.94e-05	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—AKT1—colon cancer	1.29e-06	1.94e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CASP3—colon cancer	1.28e-06	1.92e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—HRAS—colon cancer	1.27e-06	1.92e-05	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—PIK3CA—colon cancer	1.27e-06	1.92e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—HRAS—colon cancer	1.27e-06	1.91e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—PIK3CA—colon cancer	1.27e-06	1.91e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.26e-06	1.9e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—VEGFA—colon cancer	1.26e-06	1.9e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—VEGFA—colon cancer	1.26e-06	1.9e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CDKN1A—colon cancer	1.26e-06	1.9e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—KRAS—colon cancer	1.26e-06	1.89e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—KRAS—colon cancer	1.26e-06	1.89e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PPARG—colon cancer	1.25e-06	1.88e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—NRAS—colon cancer	1.25e-06	1.88e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ABCB1—colon cancer	1.25e-06	1.88e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—AKT1—colon cancer	1.25e-06	1.88e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—NRAS—colon cancer	1.25e-06	1.88e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—AKT1—colon cancer	1.24e-06	1.87e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—KRAS—colon cancer	1.24e-06	1.87e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CCND1—colon cancer	1.24e-06	1.87e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—HRAS—colon cancer	1.24e-06	1.87e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—HRAS—colon cancer	1.24e-06	1.86e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ABCB1—colon cancer	1.24e-06	1.86e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CTNNB1—colon cancer	1.23e-06	1.85e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—KRAS—colon cancer	1.23e-06	1.85e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—TYMS—colon cancer	1.23e-06	1.85e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MYC—colon cancer	1.23e-06	1.85e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MYC—colon cancer	1.23e-06	1.85e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—PIK3CA—colon cancer	1.22e-06	1.84e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TGFB1—colon cancer	1.22e-06	1.84e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TGFB1—colon cancer	1.22e-06	1.84e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PPARG—colon cancer	1.22e-06	1.84e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—TYMS—colon cancer	1.21e-06	1.83e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—AKT1—colon cancer	1.21e-06	1.83e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CDKN1A—colon cancer	1.2e-06	1.81e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—EP300—colon cancer	1.2e-06	1.81e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—EGFR—colon cancer	1.2e-06	1.8e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—EGFR—colon cancer	1.2e-06	1.8e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CASP3—colon cancer	1.19e-06	1.8e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—HRAS—colon cancer	1.17e-06	1.76e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—AKT1—colon cancer	1.17e-06	1.76e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—SRC—colon cancer	1.17e-06	1.76e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MYC—colon cancer	1.16e-06	1.75e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CCND1—colon cancer	1.16e-06	1.75e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TGFB1—colon cancer	1.16e-06	1.75e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MYC—colon cancer	1.16e-06	1.75e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TGFB1—colon cancer	1.16e-06	1.74e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—PIK3CA—colon cancer	1.16e-06	1.74e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—PIK3CA—colon cancer	1.15e-06	1.74e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—AKT1—colon cancer	1.15e-06	1.73e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CTNNB1—colon cancer	1.15e-06	1.73e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.15e-06	1.73e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—AKT1—colon cancer	1.15e-06	1.73e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—EP300—colon cancer	1.14e-06	1.72e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—PIK3CA—colon cancer	1.14e-06	1.72e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—EGFR—colon cancer	1.14e-06	1.71e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—VEGFA—colon cancer	1.14e-06	1.71e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—EGFR—colon cancer	1.13e-06	1.71e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—KRAS—colon cancer	1.13e-06	1.7e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—KRAS—colon cancer	1.13e-06	1.7e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—HRAS—colon cancer	1.13e-06	1.7e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—PIK3CA—colon cancer	1.13e-06	1.7e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—AKT1—colon cancer	1.12e-06	1.69e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CDKN1A—colon cancer	1.12e-06	1.69e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—NRAS—colon cancer	1.12e-06	1.69e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—AKT1—colon cancer	1.12e-06	1.69e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TP53—colon cancer	1.12e-06	1.68e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—EP300—colon cancer	1.11e-06	1.68e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—SRC—colon cancer	1.11e-06	1.67e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TP53—colon cancer	1.11e-06	1.66e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—EP300—colon cancer	1.11e-06	1.66e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—AKT1—colon cancer	1.1e-06	1.65e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—AKT1—colon cancer	1.09e-06	1.65e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—VEGFA—colon cancer	1.08e-06	1.63e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.08e-06	1.63e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—KRAS—colon cancer	1.07e-06	1.62e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—KRAS—colon cancer	1.07e-06	1.61e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—NRAS—colon cancer	1.07e-06	1.61e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—HRAS—colon cancer	1.07e-06	1.61e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—EP300—colon cancer	1.07e-06	1.61e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—HRAS—colon cancer	1.07e-06	1.61e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PPARG—colon cancer	1.06e-06	1.59e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—HRAS—colon cancer	1.06e-06	1.59e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ABCB1—colon cancer	1.06e-06	1.59e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MYC—colon cancer	1.04e-06	1.57e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—HRAS—colon cancer	1.04e-06	1.57e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TGFB1—colon cancer	1.04e-06	1.57e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—PIK3CA—colon cancer	1.04e-06	1.57e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—PIK3CA—colon cancer	1.04e-06	1.57e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—SRC—colon cancer	1.04e-06	1.57e-05	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—AKT1—colon cancer	1.04e-06	1.57e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—TYMS—colon cancer	1.04e-06	1.56e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—AKT1—colon cancer	1.03e-06	1.56e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CASP3—colon cancer	1.03e-06	1.55e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.03e-06	1.54e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—EGFR—colon cancer	1.02e-06	1.54e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—VEGFA—colon cancer	1.01e-06	1.52e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TP53—colon cancer	1.01e-06	1.52e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TP53—colon cancer	1.01e-06	1.52e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCND1—colon cancer	1e-06	1.51e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NRAS—colon cancer	1e-06	1.51e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—AKT1—colon cancer	9.99e-07	1.5e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MYC—colon cancer	9.97e-07	1.5e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TGFB1—colon cancer	9.94e-07	1.5e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CTNNB1—colon cancer	9.93e-07	1.49e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—PIK3CA—colon cancer	9.87e-07	1.49e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—PIK3CA—colon cancer	9.85e-07	1.48e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PTGS2—colon cancer	9.83e-07	1.48e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—EGFR—colon cancer	9.75e-07	1.47e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PIK3CA—colon cancer	9.72e-07	1.46e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PIK3CA—colon cancer	9.72e-07	1.46e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CDKN1A—colon cancer	9.7e-07	1.46e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—KRAS—colon cancer	9.66e-07	1.45e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—HRAS—colon cancer	9.62e-07	1.45e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—HRAS—colon cancer	9.62e-07	1.45e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PTGS2—colon cancer	9.6e-07	1.45e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TP53—colon cancer	9.55e-07	1.44e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TP53—colon cancer	9.53e-07	1.43e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PPARG—colon cancer	9.44e-07	1.42e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—AKT1—colon cancer	9.44e-07	1.42e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—AKT1—colon cancer	9.42e-07	1.42e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	9.35e-07	1.41e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—AKT1—colon cancer	9.34e-07	1.41e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MYC—colon cancer	9.31e-07	1.4e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TGFB1—colon cancer	9.29e-07	1.4e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—EP300—colon cancer	9.23e-07	1.39e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—AKT1—colon cancer	9.22e-07	1.39e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PPARG—colon cancer	9.21e-07	1.39e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—KRAS—colon cancer	9.21e-07	1.39e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—HRAS—colon cancer	9.13e-07	1.38e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—EGFR—colon cancer	9.11e-07	1.37e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—HRAS—colon cancer	9.11e-07	1.37e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—SRC—colon cancer	8.97e-07	1.35e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—PIK3CA—colon cancer	8.87e-07	1.34e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—VEGFA—colon cancer	8.74e-07	1.32e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PPARG—colon cancer	8.68e-07	1.31e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NRAS—colon cancer	8.63e-07	1.3e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PPARG—colon cancer	8.61e-07	1.3e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—KRAS—colon cancer	8.61e-07	1.3e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TP53—colon cancer	8.58e-07	1.29e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—AKT1—colon cancer	8.5e-07	1.28e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—AKT1—colon cancer	8.5e-07	1.28e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—PIK3CA—colon cancer	8.46e-07	1.27e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PTGS2—colon cancer	8.32e-07	1.25e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PIK3CA—colon cancer	8.25e-07	1.24e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—HRAS—colon cancer	8.21e-07	1.24e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TP53—colon cancer	8.18e-07	1.23e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PIK3CA—colon cancer	8.17e-07	1.23e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—EP300—colon cancer	8.17e-07	1.23e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ABCB1—colon cancer	8.16e-07	1.23e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—AKT1—colon cancer	8.06e-07	1.21e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—AKT1—colon cancer	8.04e-07	1.21e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MYC—colon cancer	8.04e-07	1.21e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TGFB1—colon cancer	8.02e-07	1.21e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—TYMS—colon cancer	8.01e-07	1.21e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	7.99e-07	1.2e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—EP300—colon cancer	7.99e-07	1.2e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—AKT1—colon cancer	7.94e-07	1.2e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—AKT1—colon cancer	7.94e-07	1.2e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—PIK3CA—colon cancer	7.91e-07	1.19e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—EGFR—colon cancer	7.86e-07	1.18e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—HRAS—colon cancer	7.83e-07	1.18e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TP53—colon cancer	7.65e-07	1.15e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—KRAS—colon cancer	7.43e-07	1.12e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PTGS2—colon cancer	7.43e-07	1.12e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PPARG—colon cancer	7.35e-07	1.11e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—HRAS—colon cancer	7.31e-07	1.1e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PTGS2—colon cancer	7.25e-07	1.09e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—AKT1—colon cancer	7.25e-07	1.09e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—EP300—colon cancer	6.92e-07	1.04e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—AKT1—colon cancer	6.91e-07	1.04e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PTGS2—colon cancer	6.83e-07	1.03e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PIK3CA—colon cancer	6.82e-07	1.03e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PTGS2—colon cancer	6.77e-07	1.02e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—AKT1—colon cancer	6.74e-07	1.01e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—AKT1—colon cancer	6.68e-07	1.01e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TP53—colon cancer	6.6e-07	9.94e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—AKT1—colon cancer	6.46e-07	9.73e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—HRAS—colon cancer	6.31e-07	9.51e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—EP300—colon cancer	6.18e-07	9.3e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PIK3CA—colon cancer	6.05e-07	9.1e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—EP300—colon cancer	6.03e-07	9.08e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PIK3CA—colon cancer	5.91e-07	8.9e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTGS2—colon cancer	5.79e-07	8.71e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—EP300—colon cancer	5.68e-07	8.55e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PPARG—colon cancer	5.68e-07	8.55e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—EP300—colon cancer	5.63e-07	8.48e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—AKT1—colon cancer	5.58e-07	8.4e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PIK3CA—colon cancer	5.12e-07	7.71e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—AKT1—colon cancer	4.94e-07	7.44e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—AKT1—colon cancer	4.83e-07	7.27e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—EP300—colon cancer	4.81e-07	7.25e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PIK3CA—colon cancer	4.57e-07	6.88e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTGS2—colon cancer	4.47e-07	6.72e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PIK3CA—colon cancer	4.46e-07	6.71e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PIK3CA—colon cancer	4.2e-07	6.33e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—AKT1—colon cancer	4.18e-07	6.3e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PIK3CA—colon cancer	4.17e-07	6.27e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—AKT1—colon cancer	3.73e-07	5.62e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—EP300—colon cancer	3.71e-07	5.59e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—AKT1—colon cancer	3.64e-07	5.49e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PIK3CA—colon cancer	3.56e-07	5.36e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—AKT1—colon cancer	3.43e-07	5.17e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—AKT1—colon cancer	3.4e-07	5.12e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—AKT1—colon cancer	2.91e-07	4.38e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PIK3CA—colon cancer	2.75e-07	4.14e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—AKT1—colon cancer	2.24e-07	3.38e-06	CbGpPWpGaD
